2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Study Population, Human, Adult, Animal Model
PAPER

1438 Dioxygenase independent role of TET2 in mismatch repair is essential for maintaining cellular genomic integrity

Dongxu Jiang, PhD, Atsushi Marumo2, Mamta P Sumi, PhD3, Yahan Zhang, MS4, Daniel J Vail, PhD5, Kacey O'Donnell6, Parker Yvonne7, Daniel Lindner, MD, PhD8, Valeria Visconte, PhD9, Abhay Singh, MD, MPH10, J. Joseph Joseph Melenhorst, PhD11, Jaroslaw P. Maciejewski, MD, PhD, FACP12, Babal Kant Jha, PhD13
1 Taussig Cancer Institute, Cleveland, Ohio, United States
2 Taussig Cancer Institute, Cleveland, Ohio, United States
3 Taussig Cancer Institute, Cleveland, Ohio, United States
4 Taussig Cancer Institute, Cleveland, Ohio, United States
5 Taussig Cancer Institute, Cleveland, Ohio, United States
6 Taussig Cancer Institute, Cleveland, Ohio, United States
7 Taussig Cancer Institute, Cleveland, Ohio, United States
8 Taussig Cancer Institute, Cleveland, Ohio, United States
9 Taussig Cancer Institute, Cleveland, Ohio, United States
10 Taussig Cancer Institute, Cleveland, Ohio, United States
11 Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States
12 Taussig Cancer Institute, Cleveland, Ohio, United States
13 Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States

Epigenetic dysfunctions are one of the hallmarks of myeloid neoplasia (MN).?TET2, along with TET1 and TET3 are the only known epigenetic regulators of DNA that progressively oxidize 5-methyl cytosine and facilitate its demethylation. Methylation/demethylation of CpG islands are critical for the efficient gene expression in hematopoietic stem and progenitor cells (HSPCs). TET2 mutations (TET2MT) reduces hydroxymethylation and thereby differentiation block and stem cell fitness/quantity. In here, we show loss of the N-terminal region of TET2 promotes hypermutability, resulting in the progressive and accelerated accumulation of oncogenic driver mutations.?This mechanism leads to a functional duality explaining diversity and differential penetrance of pro-leukemogenic consequences of disparate TET2MT. 
Using whole exome sequencing, long read oxford nanopore RRMS coupled with functional validation and biochemical confirmation in disparate in vitro and in vivo models, we demonstrate that TET2 directly interacts with mismatch repair (MMR) complex via MSH6 protein through its non-catalytic N-terminal domain and the complete TET2 deletion impairs MMR leading to higher mutational burden.
To test whether?TET2MT?(n= 95/495; 19%) predisposes to acquisition of additional mutations, after excluding patients with dysfunction in known DNA repair proteins (TP53, BRCA1, MSH6), we measured the total single nucleotide variants (SNVs), and compared the median SNVs in TET2MT?and TET2WT?pts.? TET2MT?pts had ~2-fold increased SNVs (p<.0001) compared to WT with truncating mutations having a 2-fold increase in median SNV (p=.03) and showing linear correlation (r=0.7) with increasing VAF, consistent with a gene-dose effect. To understand the functional role of TET2 in maintaining genomic integrity, we performed several biochemical assays. Co-immunoprecipitation (CoIP) of TET2 followed by tandem-affinity purification and LCMS/MS characterization in K562 and CMK, murine ESC and MEL cells identified all major components of the DNA mismatch repair (MMR) complex as part of the TET2 interactome. MSH6, an essential component of MMR complex, was a common TET2’s interaction in different human cell lines and mouse mESCs. TET2-MSH6 interaction was validated by reverse CoIP using anti-MSH6. By ectopic expression of TET2 truncated constructs followed by CoIP, MSH6 binding site was mapped to non-catalytic N-terminal amino acid segment 460-1047 of TET2. In addition, we found that complete deletion of TET2 reduced MMR efficiency while catalytic domain (1133-2002) deletion has no effect as reflected in the number of surviving clones under genotoxic stress. Ectopic expressions of N terminal domain restored MMR deficiency in TET2ko cells while catalytic domain could not rescue this defect, suggesting that enzymatic activity of TET2 is dispensable for its MMR function. MSH6 protein levels showed a 2-fold decrease (p=0.008) in TET2ko cells without any change in the transcript levels. The increased MSH6-associated ubiquitination in TET2ko cells, which was reversed by proteasome inhibitor MG132 suggested its proteasomal control. The ectopic expression of N-terminal TET2, is necessary and sufficient to stabilize MSH6, implicating that the stability of MMR complex is regulated by the non-catalytic N-terminal of TET2. This was further confirmed in vivo using specific small molecule TET dioxygenase inhibitor (TETi) that does not disrupt the structural integrity of TET2 or levels of MSH6. Mice treated for 12 months with TETi (40mg/Kg) along with vehicle and Tet2ko controls (n=3/group) demonstrated that complete Tet2 loss significantly increased mutational burden (1.5-fold) while TETi has no effect. In contrast, TETi-treated TET2 proficient mice, did not exhibit any marked increase in mutational burden despite having elevated 5mC due to TETi. In addition, leukemia-associated genes were associated with Tet2ko not in TETi group. In comparison to wild type TETi treated and Tet2ko mice exhibited a cumulative ~1.5-fold increase in the number of mutated leukemia-associated genes and the total SNV across the analyzed genes.
In summary, we report that TET2 directly binds to MSH6 through its non-catalytic N-terminal domain and recruits MMR complex to the site of mismatch around CpG island to facilitate MMR. Given that MSH6 is known to bind 5hmC, TET2 may guide MSH6 to TET2-dependent DNA loci directly linking TET2MT to genomic instability that can be therapeutically exploited.

Dongxu Jiang, PhD: No relevant conflicts of interest to declare.